NASDAQ: GILDGilead Sciences Revenue
Gilead Sciences revenue was $29.09B for the trailing 12 months ending Sep 30, 2025, with 6,410% growth year over year. Quarterly revenue for the quarter (Q3 2025) ending on Sep 30, 2025 was $7.8B, up 9.7% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, GILD annual revenue was $28.8B, with 6% growth year-over-year.
GILD past revenue growth
How has GILD's revenue growth performed historically?
Company
2.78%
Industry
18.32%
Market
21.98%
GILD's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
GILD's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
GILD's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance
GILD revenue history
Current Revenue
$29.1B
Current Earnings
$8.1B
Current Profit Margin
27.9%
GILD's has not demonstrated consistent... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance
Be the first to know when GILD announces revenue.
GILD Revenue History By Year
| GILD Yearly Revenue | GILD Revenue | GILD Change | GILD Revenue Growth |
|---|---|---|---|
| 2024-12-31 | $28.75B | $1.64B | +6.04% |
| 2023-12-31 | $27.12B | -$165.00M | -0.60% |
| 2022-12-31 | $27.28B | -$24.00M | -0.09% |
| 2021-12-31 | $27.31B | $2.62B | +10.60% |
| 2020-12-31 | $24.69B | $2.24B | +9.98% |
| 2019-12-31 | $22.45B | $322.00M | +1.46% |
| 2018-12-31 | $22.13B | -$3.98B | -15.24% |
| 2017-12-31 | $26.11B | -$4.28B | -14.09% |
| 2016-12-31 | $30.39B | -$2.25B | -6.89% |
| 2015-12-31 | $32.64B | $7.75B | +31.13% |
| 2014-12-31 | $24.89B | $13.69B | +122.19% |
| 2013-12-31 | $11.20B | $1.50B | +15.46% |
| 2012-12-31 | $9.70B | $1.32B | +15.70% |
| 2011-12-31 | $8.39B | $435.97M | +5.48% |
| 2010-12-31 | $7.95B | $938.04M | +13.38% |
| 2009-12-31 | $7.01B | $1.68B | +31.40% |
| 2008-12-31 | $5.34B | $1.11B | +26.14% |
| 2007-12-31 | $4.23B | $1.20B | +39.78% |
| 2006-12-31 | $3.03B | $997.74M | +49.19% |
| 2005-12-31 | $2.03B | $703.78M | +53.13% |
| 2004-12-31 | $1.32B | $456.76M | +52.63% |
| 2003-12-31 | $867.86M | $401.07M | +85.92% |
| 2002-12-31 | $466.79M | $233.02M | +99.68% |
| 2001-12-31 | $233.77M | $38.21M | +19.54% |
| 2000-12-31 | $195.56M | $26.58M | +15.73% |
| 1999-12-31 | $168.98M | $17.86M | +11.82% |
| 1998-12-31 | $151.12M | $18.86M | +14.26% |
| 1997-12-31 | $132.26M | $98.84M | +295.75% |
| 1996-12-31 | $33.42M | $28.50M | +578.99% |
| 1995-03-31 | $4.92M | N/A | N/A |
Gilead Sciences Revenue FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.